IP Counsels Committee Conference

2018 BIO INTELLECTUAL PROPERTY COUNSELS COMMITTEE



2018 SPRING CONFERENCE

APRIL 11–13, 2018
New Orleans, LA

PROGRAM GUIDE

25 YEARS OF BIO INNOVATION

Program Guide sponsored by FORRESTERS Clear direction

IP Counsels Committee Conference



FALL CONFERENCE

NOVEMBER 14-16, 2018
Indianapolis, IN

2018

BIO INTELLECTUAL PROPERTY COUNSELS COMMITTEE

TABLE OF CONTENTS

CLE CREDIT INFORMATION

BIO will be offering continuing legal education credit at the 2018 IPCC Spring Conference. Application for CLE credit will be submitted in California and Virginia. Attorneys will be notified if BIO receives credit approval. Attorneys needing CLE credit from other states are welcome to sign in, pick up the CLE forms and apply to their jurisdictions on their own. BIO will provide you with all the materials and documentation required to apply with your individual state CLE Boards.

NOTICE AND DISCLAIMER

All sessions will take place at the Royal Sonesta New Orleans, in the Grand Ballroom (lobby level), unless otherwise noted.

WEDNESDAY, APRIL 11, 2018

1:00 pm - 4:30 pm — **REGISTRATION OPEN**

12:00 pm – 3:00 pm — **IPCC BUSINESS MEETING & WORKING LUNCHEON**
**Open to IP Counsels Committee company members only*
****Location: Royal Conti Room, Lower Level***

3:00 pm – 3:15 pm — **REFRESHMENT BREAK**
Sponsored by: **Marshall Gerstein & Borun LLP**

3:15 pm – 4:30 pm — **OPENING SESSION: ANTIBODY PATENTING: WITHOUT EXCEPTION OR ELIGIBILITY**
Sponsored by: **McDonnell Boehnen Hulbert & Berghoff LLP**

The Federal Circuit's decision in Amgen Inc. v. Sanofi eliminated the "well-characterized antigen" test for compliance with the written description requirement for antibodies, thereby affecting how the courts and U.S. Patent and Trademark Office should apply the written description requirement to properly circumscribe the scope of claims to antibodies. In addition, the U.S. Patent and Trademark Office's Interim Guidance on Patent Subject Matter Eligibility, and in particular, the Office's example on antibodies, delineated patent ineligible antibodies from those that are patent eligible. This session will address compliance with the written description requirement and the subject matter eligibility of claims to antibodies, as well as differences in the patenting of antibodies in the United States and Europe.

MODERATOR:
- **Donald Zuhn,** *Partner,* McDonnell Boehnen Hulbert & Berghoff LLP

PANELISTS:
- **Cara Coburn,** *Assistant General Counsel,* Genentech
- **Kristan Lansbery,** *Director, Patent Attorney,* Regeneron Pharmaceuticals, Inc.
- **Charlotte Teall,** *Equity Partner,* Forresters

WEDNESDAY, APRIL 11, 2018 CONTINUED

4:30 pm – 5:00 pm

OPENING KEYNOTE FEATURING JOSEPH MATAL, USPTO

Sponsored By: **Seed Intellectual Property Law Group LLP**

Former Interim Director of the United States Patent and Trademark Office and Senate Judiciary Committee staff for the America Invents Act

5:30 pm – 7:30 pm

WELCOME RECEPTION

Welcome Reception at Historic Napoleon House

Sponsored by: **Brinks Gilson & Lione**

Napoleon House
500 Chartres Street
(.2 miles, 5 minute walk from Royal Sonesta)

Few places capture the essence of historic New Orleans like the Napoleon House: A 200 year old landmark and home of Nicholas Girod, mayor of New Orleans from 1812 to 1815. Girod offered his residence to Napoleon in 1821 as a refuge during his exile – and even though Napoleon never made it, the name stuck. Join your IPCC colleagues for cocktails and light bites in the ornate rooms and balconies that would have housed Bonaparte in this truly unique French Quarter destination.

Our walking group from the Royal Sonesta will depart from the BALLROOM LOBBY (via Conti Street exit) at 5:25 pm.

THURSDAY, APRIL 12, 2018

8:30 am – 9:30 am

NETWORKING BREAKFAST

Sponsored by: **Morrison & Foerster LLP**

9:30 am – 10:45 am

SESSION 1: LEGAL DEVELOPMENTS, CUTTING-EDGE CASES AND PRACTICAL IMPLICATIONS

Sponsored by: **WilmerHale**

This panel will present on significant developments from the US Supreme Court, as well as notable lower court decisions, illustrating new developments and how recent trends in the law could impact the biotechnology industry. Topics will include, among others, venue jurisprudence post-TC Heartland and appeals from inter partes review, including standing to appeal and the intersection of patent and administrative law.

Speakers will discuss practical implications and tips from their varying perspectives as trial counsel, appellate counsel, and in-house counsel with emphasis on how to stay prepared in this ever-changing landscape.

MODERATOR:

- **Lisa Pirozzolo,** *Partner and Co-Chair, Intellectual Property Litigation Practice Group,* WilmerHale

PANELISTS:

- **Brenda Hefti,** *Vice President, Intellectual Property and Licensing,* Exelixis
- **Mark Rachlin,** *Senior Patent Counsel,* GlaxoSmithKline
- **Thomas Saunders,** *Appellate and Supreme Court Litigation Partner,* WilmerHale

10:45 am – 11:00 am

REFRESHMENT BREAK

Sponsored by: **Marshall Gerstein & Borun LLP**

THURSDAY, APRIL 12, 2018 CONTINUED

11:00 am – 12:15 pm

SESSION 2: PATENT ELIGIBILITY IN A POST MAYO WORLD

Sponsored by: **Fenwick & West LLP**

This panel will explore recent cases impacting the patent eligibility of inventions relating to diagnostics and personalized medicine, and discuss the implications for obtaining patent protection in this space.

MODERATOR:

- **David Tellekson,** *Partner,* Fenwick & West LLP

PANELISTS:

- **Ewa Davison, Ph.D.,** *Associate,* Fenwick & West LLP
- **Matthew Gordon,** *Senior Director, Legal Affairs,* Myriad Genetics
- **Elias Lambiris,** *Director, Global IP Litigation,* Novozymes

12:30 pm – 1:45 pm **LUNCH BUFFET**

2:00 pm – 3:15 pm

SESSION 3: FROM ALLEGATION TO ADJUDICATION: PREPARING FOR PATENT LITIGATION

Sponsored by: **Rothwell Figg**

This panel will discuss how to prepare for litigation in Hatch-Waxman and Biosimilar cases. Speakers will offer practical tips on how to prepare your strongest case, prepare a budget, select litigation counsel, identify and retain experts, preserve documents, select a favorable venue, determine a litigation strategy, manage IPRs, position a case for settlement and for trial, and more. The panel is targeted at smaller companies that may have little or no experience litigating patent issues, but will offer insights and updates for seasoned litigators as well. Come with your questions for this lively panel of in-house and outside counsel who will share their experiences as both defendants and plaintiffs.

MODERATOR:

- **Steven Lieberman,** *Partner Specializing in Patent Litigation,* Rothwell Figg

PANELISTS:

- **Jennifer Nock,** *Associate,* Rothwell Figg
- **Dan Troy,** *Senior Vice President & General Counsel,* GlaxoSmithKline
- **John Weidenbruch,** *General Counsel,* Epizyme

3:15 pm – 3:30 pm **REFRESHMENT BREAK**

3:30 pm – 4:45 pm

SESSION 4: WHAT'S ON THE HORIZON? A FIRESIDE CHAT WITH CHIEF JUDGE RUSCHKE

Sponsored by: **Foley Hoag LLP**

This session is an opportunity to hear from The Honorable David Ruschke, Chief Judge for the Patent Trial and Appeal Board, US Patent and Trademark Office, about the latest in U.S. Patent and Trial Appeal Board (PTAB) procedures and practices, recent trends, and potential changes to the PTAB in light of the confirmation of new Director Andrei Iancu.

MODERATOR:

- **Barbara Fiacco,** *Partner,* Foley Hoag LLP

5:30 pm – 8:30 pm

Fitzpatrick | we are IP.

FRENCH QUARTER SCAVENGER HUNT AND OFFSITE DINNER RECEPTION

**RSVP Only*

Dinner Reception will be held at 7:00 pm at Marché
Sponsored by **Fitzpatrick, Cella, Harper & Scinto**

Marché:
914 N. Peters St (follow cut-through to the "Dutch Alley" for restaurant entrance; *.6 miles, 12 minute walk from Royal Sonesta*)

Get to know a side of the French Quarter beyond Mardi Gras - with supernatural stories, historic landmarks, and beautiful outdoor enclaves during our (competitive!) 75-minute mobile scavenger hunt. Lead your team to bragging-rights-glory before dinner at the rooftop venue Marché, located in the French Market of New Orleans, with sweeping views of the Mississippi River. Located just 1.5 blocks from the original Café du Monde - don't forget to pick up a beignet and coffee on your way home!

The group will meet outside of the IPCC session room no later than 5:30 pm to begin the scavenger hunt (Pro Tip: bring comfy shoes!). All hunts will conclude within walking distance to the reception dinner, where scavenger hunt winners and team superlatives will be announced!

FRIDAY, APRIL 13, 2018

8:30 am – 9:30 am

NETWORKING BREAKFAST

Sponsored by: **Morrison & Foerster LLP**

9:30 am – 10:45 am

SESSION 5: DID YOU FORGET ANYTHING? DEALING WITH THE OVERLOOKED PROVISIONS OF THE AIA

Sponsored by: **Foley Hoag LLP**

Nearly seven years have passed since enactment of the America Invents Act (AIA). While provisions, such as post-issuance proceedings, are frequent topics of discussion, other infrequently-encountered areas have often baffled patent practitioners. In this panel, we will discuss the forgotten provisions of the AIA, including derivation proceedings, supplemental examination, prior art submissions, grace periods for inventor disclosures, and others.

MODERATOR:

- **Donald R. Ware,** *Partner and Chair of the Patent Litigation Group,* Foley Hoag, LLP

PANELISTS:

- **Rebecca M. McNeill,** *Founding Partner,* McNeill Baur PLLC
- **Jane E. Remillard,** *Partner,* Nelson Mullins Riley & Scarborough LLP

10:45 am – 11:00 am

REFRESHMENT BREAK

Sponsored by: **Marshall Gerstein & Borun LLP**

11:00 am – 12:15 pm

SESSION 6: IF A TREE FALLS IN THE FOREST, DOES IT MAKE A SOUND? MYTHS AND REALITIES OF "EVERGREENING" PATENTS

Sponsored by: **Fenwick & West LLP**

This panel will discuss secondary drug patents, also known as "evergreening" patenting. Panelists will explain the difference between primary and secondary patents, and address the myths and realities concerning secondary patents and their impact on market exclusivity of branded drugs.

MODERATOR:

- **Melanie Mayer,** *Partner,* Fenwick & West LLP

PANELISTS:

- **Paul Fehlner,** *Former Global Head of IP,* Novartis
- **Hans Sauer, Ph.D., J.D.,** *Deputy General Counsel and Vice President for Intellectual Property,* Biotechnology Innovation Organization
- **Chuck Sholtz,** *Vice President, Intellectual Property,* Coherus Biosciences

12:15 pm

PROGRAM ADJOURNS

Program Agenda

MISSION AND GUIDELINES

INTELLECTUAL PROPERTY COUNSELS COMMITTEE (IPCC)

COMMITTEE CHAIR

Chair: **Kenneth Dow,** *Vice President, Patents & Assistant Patent Counsel,* Johnson & Johnson

SUBCOMMITTEES AND WORKING GROUPS

If you are interested in joining any of the following subcommittees, please contact **Austin Donohue** at **adonohue@bio.org**.

AMICUS SUBCOMMITTEE

Chair: **Brian P. Barrett,** *Associate General Patent Counsel*, Eli Lilly

PTO WORKING GROUP

Chair: **Jason Ferrone,** *Vice President, Patents & Corporate Development*, ISIS Pharmaceuticals, Inc.

INTERNATIONAL IP WORKING GROUP

Chair: **Li Westerlund,** *Vice President of Global Intellectual Property*, Bavarian Nordic Group

MISSION

To promote strong, predictable intellectual property protection and efficient transfer of IP rights for the biotechnology industry domestically and internationally.

ELIGIBILITY FOR PARTICIPATION

In order to be eligible for membership, the interested party MUST be a member of BIO. Unless otherwise directed by the chair of the IPCC, committee members MUST represent a member biotechnology company either as in-house patent counsel or outside patent counsel. While a law degree is not required, many committee activities require detailed knowledge of patent law.

PARTICIPATION

The committee meets bi-annually in-person. There are also opportunities for working groups to meet on an ad hoc basis or to give comments throughout the year on papers, letters, and other correspondence sent out on behalf of BIO's members.

RESPONSIBILITIES

- The Intellectual Property Counsels Committee (IPCC) is responsible for developing domestic and international intellectual property policy that benefits the biotechnology industry.
- The committee is responsible for reviewing and commenting on proposed intellectual property legislation.
- The committee is responsible for reviewing and commenting on IP-related regulations from Federal agencies, including the United States Patent and Trademark Office (PTO) and the National Institutes of Health (NIH).
- The committee works with BIO staff to brief Members of Congress and officials of the governmental agencies such as the PTO, the U.S. State Department, the Federal Trade Commission, the U.S. Trade Representative, and the NIH on intellectual property matters.
- The committee actively participates in efforts to influence legislation, treaties, jurisprudence and practice in a manner most beneficial to the continued positive development of the biotechnology industry.
- The committee, from time to time, approves the filing of amicus briefs in cases that have an impact on the biotechnology industry.
- Committee members may be asked to help develop IP-related position papers, white papers and educational materials.
- Committee members may be asked to formulate comments and testimony on various IP-related guidelines and regulations.

POLICY APPROVAL PROCESS

Substantive matters designed to become the official position of BIO are sent as recommendations of the IPCC to the Board of Directors Standing Committee on Intellectual Property for first review. The Standing Committee on Intellectual Property will discuss and, as appropriate, determine changes in the recommendations.

The Standing Committee will then either return substantive matter to the IPCC for further comment and revision or refer the matter to the full Board of Directors for consideration.

PAST ACCOMPLISHMENTS

The IPCC has helped develop and pass the American Inventor Protection Act of 1999 and the America Invents Act of 2011; developed BIO's positions on patent reform; and engaged in Patent Reform negotiations on the Hill. The committee has developed BIO's position and testimony on patenting genetic materials, university and industry partnerships/technology transfer and intellectual property and competition policy. The committee has also filed comments to relevant PTO proposed rule-making notices most notably the PTO's utility and written description guidelines; PTO claims and continuation rules, "three track" examination, the PTO's "Patents for Humanity" program, and implementing regulations for the America Invents Act. The committee has also filed numerous amicus briefs in cases of relevance to the biotechnology industry, including *Monsanto v. Bowman, Prometheus v. Mayo, Therasense v. Becton Dickinson, AMP v. Myriad Genetics, Stanford v. Roche, and Microsoft v. i4i,* among others. The committee also files annual comments to, and participates in the Special 301 process highlighting countries with IP concerns, at the Office of the United States Trade Representative. Also, on the international front, the committee has developed BIO's position on substantive patent law harmonization, intellectual property in global health, and intellectual property and access to genetic resources.

BIO STAFF CONTACTS

Hans Sauer, *Deputy General Counsel, Intellectual Property,* **hsauer@bio.org**

Melissa Brand, *Associate Counsel and Director, Intellectual Property Policy,* **mbrand@bio.org**

Austin Donohue, *Coordinator, Legal and Intellectual Property,* **adonohue@bio.org**

BIO ANTITRUST STATEMENT

All BIO meeting activities shall be conducted to abide strictly by all applicable antitrust laws. The antitrust principles discussed below apply to every meeting or conference call, no matter how informal, in which BIO members and staff gather under BIO's auspices.

Antitrust violations do not require proof of a formal agreement. A violation may be alleged based upon the mere appearance of unlawful activity. For example, discussion of a sensitive topic, such as price, followed by parallel action by those involved or present at the discussion, may be sufficient to show a price-fixing conspiracy. It is therefore important for speakers and attendees at BIO meetings to avoid discussing confidential business plans or information that is competitively sensitive, including the following:

- **Company-specific current or future prices,** including discounts, rebates, and pricing plans or policies;
- **Sales or research in particular markets or sales to particular customers,** including whether or how to sell in specific markets, whether to bid for specific business or participate in specific programs, conditions (such as resale restrictions) applicable to particular private or governmental customers, and whether to conduct research in particular areas;
- **Advertising and promotion plans,** including expected levels of advertising, which products to advertise, content of advertising, and future plans for the number of sales representatives and levels of expenditure on sales activities; and
- **How companies might or should respond in the marketplace** (such as by changing pricing, sales, distribution, or advertising policies) in light of existing or pending laws or regulations or current business or policy climates, including the suggestion of boycotts, or refusals to deal with, particular markets or customers.

This list of generally prohibited topics is not exhaustive. By the same token, it is generally fine to discuss the nature of government regulations or policies on pricing, advertising and other aspects of pharmaceutical or biotechnology company business and advocacy efforts to address these government regulations or policies, as long as the discussions are limited to matters of public policy and government advocacy.

Criminal prosecution by federal or state authorities is a very real possibility for violations of the antitrust laws. Imprisonment, fines or treble damages may ensue. BIO, its members and guests must conduct themselves in a manner that avoids even the perception or slightest suspicion that antitrust laws are being violated. Whenever uncertainty exists as to the legality or propriety of conduct, including during any meeting or discussion, obtain legal advice by contacting Peter McHugh, BIO's General Counsel & SVP, Legal at (202) 962-6671.

The antitrust laws do not prohibit meetings among members of a trade association in order to petition government or respond to government initiatives, to educate and inform the public, or to suggest quality and safety standards, thereby promoting economic welfare and the vitality of our several industries. It is in this spirit that BIO conducts its meetings and conferences.

BIO Antitrust Statement

Biotechnology Innovation Organization

CONFERENCE ORGANIZER

THE BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)

is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling "innovations transforming our world" and the BIO Newsletter is the organization's bi-weekly email newsletter.

BakerHostetler

BAKERHOSTETLER LLP

www.bakerlaw.com

Contact: Benjamin C. Hsing, *Partner,* **bhsing@bakerlaw.com**
(212) 589-4260

BakerHostetler helps clients leverage their intellectual property assets to create maximum revenue and growth, along with a distinct competitive edge. BakerHostetler counsels many life sciences clients, and as a result has a deep understanding of the life sciences industry and their leaders' need as well as a practical view of the issues facing the industry.

BRINKS GILSON & LIONE 100 YEARS OF IP LAW

BRINKS GILSON & LIONE

Brinks Gilson & Lione provides world-class IP services and solutions - including counsel for litigation and administrative proceedings, strategic planning and risk management, and patent portfolio procurement and management - to clients ranging from start-ups and entrepreneurs to multinational corporations, from academic institutions to investors in technology.

Our Biotechnology and Pharmaceutical practice group has more than 45 experienced attorneys and patent agents who are deeply versed in the complex and ever-evolving areas of the law specific to these industries.

Fenwick FENWICK & WEST LLP

FENWICK & WEST LLP

www.fenwick.com

Contact: John D. Livingstone, *Partner,* **john.livingstone@finnegan.com**
(404) 653-6449

Fenwick & West LLP provides comprehensive legal services to ground-breaking technology and life sciences companies – at every stage of their lifecycle – and the investors that partner with them. For 40 years, Fenwick's life sciences group have served emerging and established companies in the life sciences, mHealth, digital heath and healthcare IT industries, as well as leading research institutions.

FINNEGAN

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP

www.finnegan.com

With more than 350 professionals focused on intellectual property, Finnegan is one of the largest IP law firms in the world. With legal and technical experience in virtually every industry and technology, the firm practices all aspects of U.S. and European patent, trademark, copyright, and trade secret law.

Fitzpatrick | we are IP.

FITZPATRICK, CELLA, HARPER & SCINTO

www.fitzpatrickcella.com

Contact: **Linda Ficano,** *Director of Marketing and Business Development,* **lficano@fchs.com** (212) 218-2284

At Fitzpatrick, IP is not just a practice area – it is our sole focus. We are widely acknowledged as one of the premier IP firms in the country practicing all areas of IP law. Our technical acumen plus legal ability result in razor-sharp professional services in a multitude of industries.

FOLEY HOAG LLP

FOLEY HOAG LLP

www.foleyhoag.com

Contact: **Don Ware,** *Partner*, **Dware@foleyhoag.com**

Foley Hoag is a dynamic law firm that represents biopharma clients in diverse areas such as life sciences, patent litigation, prosecution and strategy, patent post-grant proceedings, corporate finance/securities, FDA/reimbursement, and strategic alliances. From our offices in Boston, New York, Washington, D.C., and Paris, we provide strategic legal advice that is tailored to each of our clients' unique goals.

FORRESTERS
Clear direction

FORRESTERS

www.forresters.co.uk

Contact: **Jon Gowshall,** *Partner, Head of Life Sciences and Chemistry Department,* **jgowshall@forresters.co.uk**

At Forresters, we provide clear, sensible and practical advice on intellectual property, including patents, trade marks, designs and copyright, in Europe and across the world. We like to take a collaborative approach with our clients, drawing on their knowledge to ensure that we understand what they want to achieve.

Conference Organizers and Sponsors

MARSHALL, GERSTEIN & BORUN LLP

www.marshallip.com

Contact: **Katherine L. Neville, Ph.D.,** *Partner,* **kneville@marshallip.com**
(312) 474-6633

Marshall Gerstein is dedicated exclusively to the practice of IP law and help clients achieve their IP goals in more than 150 countries on six continents. The Firm assists clients in all phases of the IP life cycle, including securing rights, conducting transactions, and litigating and resolving disputes.

MCDERMOTT WILL & EMERY

https://www.mwe.com

Contact: **Angus McQuilken**, *Business Development Manager – Life Sciences*, **amcquilken@mwe.com** (617) 535-4052

For life sciences leaders seeking to clear their path to success, McDermott Will & Emery offers mission-first business solutions equally informed by market intelligence and proven experience. We harness the power of collaboration to bring the right combination of people, skills and knowledge to bear at the right time.

MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP

www.mbhb.com

Contact: **Kevin Noonan,** *Partner*, **noonan@mbhb.com** (312) 913-2145
Donald Zuhn, Jr., *Partner*, **zuhn@mbhb.com** (312) 913-2132

McDonnell Boehnen Hulbert & Berghoff LLP provides creative, pragmatic business solutions across a myriad of technology areas through a variety of intellectual property services, including litigation, prosecution, and general client counseling.

MORRISON & FOERSTER LLP

www.mofo.com

Contact: **David A. Manspeizer,** *Partner*, **dmanspeizer@mofo.com**
New York, (212) 468-8015
Greg Chopskie, *Partner,* **gchopskie@mofo.com**
Washington D.C., (202) 887-8731

Morrison & Foerster represents more than 600 life sciences companies. With our depth of technological expertise, wealth of business insight, renowned legal skill, and global presence, our Life Sciences Group, including more than 65 PhDs, is helping clients strike the balance between innovative discovery and purposeful business planning to assure their continued success.

NUTTER

www.nutter.com

Contact: Konstantin Linnik, *Partner,* Nutter, **linnik@nutter.com**
(617) 439-2875

Nutter is a full-service, Boston-based law firm that works with life sciences clients throughout their product life cycle. We understand this business and its pressures: research and development; intellectual property and licensing, clinical trials, government regulations, M&A and collaborations. We help transform ideas and goals into viable strategies and better outcomes.

ROTHWELL FIGG

www.rfem.com

Contact: Steven Lieberman, *Member,* **slieberman@rfem.com**
(202) 783-6040

Rothwell Figg is one of the most highly regarded IP firms in the U.S. The 40 lawyers in our office in Washington, DC, have litigated hundreds of pharmaceutical and biotech patent cases over the past 30 years, and also have deep experience in handling IPRs, interferences, patent prosecution, and opinion work.

Seed IP
Seed Intellectual Property Law Group LLP

SEED INTELLECTUAL PROPERTY LAW GROUP LLP

www.SeedIP.com

Contact: Jeffrey C. Pepe, Ph.D., *Partner*, **JeffP@SeedIP.com**
(206) 622-4900

Seed Intellectual Property Law Group provides services in all areas of IP law, with extensive experience across many life science disciplines ranging from immunology to cell and molecular biology to pharmaceuticals to biofuels, and more. Seed's team approach facilitates comprehensive strategy development to address a client's unique IP needs.

WILMERHALE®

WILMERHALE

www.wilmerhale.com

Contact: Christopher Noyes, *Partner*, **Christopher.Noyes@wilmerhale.com**
(212) 295-6823

WilmerHale is a leading international law firm experienced in providing comprehensive solutions for the intellectual property challenges of our life sciences clients. From biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth, the firm has been deeply involved landmark intellectual property disputes for over four decades.

OPENING REMARKS

JOSEPH MATAL

Formerly Performed the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

In his former role performing the functions and duties of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO), Joseph Matal provided leadership and oversight to one of the largest intellectual property offices in the world, with over 12,000 employees and an annual budget of over $3 billion. Mr. Matal also served as the principal advisor to the President, through the Secretary of Commerce, on domestic and international intellectual property policy matters.

Prior to this, Mr. Matal served as acting Chief of Staff for the agency, and advised the director on legislative matters. Mr. Matal has also been an Associate Solicitor in the USPTO's Office of Solicitor. In this role, Mr. Matal briefed and argued appeals of patent and trademark decisions before the U.S. Court of Appeals for the Federal Circuit and the U.S. District Court, and assisted in the development of legal positions taken by the U.S. Solicitor General in patent and copyright cases before the U.S. Supreme Court.

Mr. Matal previously served as the General Counsel of the Judiciary Committee for former Senator Jeff Sessions (R-AL), and as a Judiciary Committee Counsel to former Senator Jon Kyl (R-AZ). He was the principal staff drafter and negotiator of legislation that became the Leahy-Smith America Invents Act, the first comprehensive patent law overhaul since 1952. Mr. Matal has a bachelor's degree from Stanford University, and a law degree from the University of California at Berkeley.

OPENING SESSION: ANTIBODY PATENTING: WITHOUT EXCEPTION OR ELIGIBILITY

DONALD L. ZUHN, JR., PH.D.

Partner, McDonnell Boehnen Hulbert & Berghoff LLP

Donald L. Zuhn, Jr., Ph.D., is a partner at McDonnell Boehnen Hulbert & Berghoff LLP, where his practice focuses on biotechnology and pharmaceutical patent prosecution, litigation, counseling, and licensing. He received his Ph.D. from the University of Illinois at Chicago, and graduated *summa cum laude* from the John Marshall Law School, where he helped found the *John Marshall Review of Intellectual Property Law*. Dr. Zuhn is also the editor and co-founder of the Patent Docs weblog (www.patentdocs.org), which focuses on developments in patent law, and which has been named to the American Bar Association's "Blawg 100," recognizing the 100 best legal blogs.

CARA COBURN

Assistant General Counsel, Genentech, Inc.

Cara Coburn is Assistant General Counsel at Genentech, Inc. where her practice focuses on large molecule matters. Prior to joining Genentech, she was an attorney at Morrison & Foerster, where her practice focused on patent prosecution, and served as a law clerk for Judge Raymond Clevenger III at the Court of Appeal for the Federal Circuit. Cara received her JD from the University of California, Berkeley, School of Law and a PhD in biochemistry from the University of California, San Francisco.

KRISTAN L. LANSBERY, PH.D.

Director, Patent Attorney, Regeneron Pharmaceuticals

Kristan L. Lansbery, Ph.D. is an attorney with corporate and law firm leadership experience. As a Director within the legal department at Regeneron Pharmaceuticals, she oversees a team responsible for global patent protection of downstream platform technologies, trade secret protection, and freedom to operate. In that capacity, she partners with multiple research

and business functions to assist the scientists, regulatory group, and other corporate stakeholders. Examples of her work at Regeneron include developing processes for multiple scientific and business groups to designate trade secrets and partnering with litigators to prepare for product launches.

Prior to Regeneron, Dr. Lansbery was a partner at Arnold & Porter LLP, where she managed teams responsible for the worldwide prosecution of life science patent portfolios. She also was lead counsel on several contentious matters before the Patent Trial and Appeal Board, and she has successfully argued ex parte appeals and litigated disputes related to polymerase chain reaction, drug eluting stents, therapeutic antibodies, and diagnostic nucleic acids.

Dr. Lansbery's practice is recognized by multiple publications, including IAM Patent 1000, and she has taught Biotechnology and Patent Law at Georgetown University. She earned her Ph.D. in Molecular Cell Biology from Washington University in St. Louis, and attended law school at the George Washington University.

CHARLOTTE TEALL

Equity Partner, Forresters

Charlotte is a European and UK patent attorney in the life sciences team at Forresters. Charlotte has a background in biochemistry from Imperial College London and also holds an MSc in IP management from Queen Mary, London.

Charlotte works on all aspects of patent law in Europe, the UK and overseas. She is primarily involved in the drafting and European prosecution of patent applications in the fields of biotechnology, pharmaceuticals and medical devices. Charlotte also has a strong SPC practice and regularly navigates clients through the complex process of securing SPC protection. Charlotte is primarily based in London, but spends several weeks each year in Munich for dealings with the EPO.

Outside of work, Charlotte is an obstacle course racer, motorbiker and scuba diver (not all at the same time though!). She is lucky enough to have represented the UK at the Obstacle Course Racing (OCR) European and World Championships.

SESSION 1: LEGAL DEVELOPMENTS, CUTTING-EDGE CASES AND PRACTICAL IMPLICATIONS

LISA PIROZZOLO

Partner and Co-Chair, Intellectual Property Litigation Practice Group, WilmerHale

Lisa Pirozzolo is a partner at WilmerHale and co-chairs the firm's Intellectual Property Litigation Practice. She has over twenty years of experience representing clients in patent and licensing disputes, with a particular focus on life sciences matters. Ms. Pirozzolo has substantial trial experience and has served as counsel of record in many Hatch-Waxman cases. She has also argued before the US Court of Appeals for the Federal Circuit and represented clients before the Patent Trial and Appeal Board and the International Trade Commission. She has been recognized as a leader in intellectual property law in *Chambers USA: America's Leading Lawyers for Business* every year since 2008, was honored as New England General Patent Litigator of the Year in 2017 and named a Life Sciences Star for intellectual property in the 2012-2017 editions of *LMG Life Sciences*. Ms. Pirozzolo was also named the Boston Litigation - Intellectual Property Lawyer of the Year for 2018 by *Best Lawyers in America*. She is a graduate of Yale University and obtained her JD, *cum laude*, from Cornell Law School.

BRENDA HEFTI

Vice President of Intellectual Property and Licensing, Exelixis

Brenda Hefti is Vice President of Intellectual Property and Licensing at Exelixis, Inc. Exelixis is a commercial-stage biotech company with a focus in oncology therapeutics. Exelixis currently has three prescription oncology products for sale worldwide which originated from its internal discovery efforts – Cometriq, Cabometyx, and in partnership with Genentech (Roche), Cotellic. Exelixis is also in the process of rebuilding its discovery pipeline through both internal research and in-licensing efforts. In her role as in-house counsel at Exelixis, Dr. Hefti manages the company's extensive IP portfolios for its commercial products and research assets, leads complex transactions for research, clinical, and commercial collaborations and licensing, and serves as the primary legal

resource for Exelixis' clinical development programs. Dr. Hefti received her PhD from the University of Wisconsin, Madison in Neuroscience, and graduated *cum laude* from the University of California Hastings College of the Law.

MARK RACHLIN

Senior Patent Counsel, GlaxoSmithKline

Mark Rachlin is senior patent counsel specializing in litigation for GlaxoSmithKline. His work includes Hatch-Waxman, biopharma cases and IPR's. Mr. Rachlin has also served as in-house counsel with two major chemical companies, been associated with the firm of Sidley Austin and was a trial attorney with the US Department of Justice.

THOMAS SAUNDERS

Appellate and Supreme Court Litigation Partner, WilmerHale

Tom Saunders is a partner in WilmerHale's Appellate and Supreme Court Litigation Practice. His practice focuses on appellate and government and public policy litigation with an emphasis on intellectual property. Mr. Saunders has extensive experience representing clients in patent and copyright cases and has built a reputation as a leading advocate in high-stakes litigation before the Federal Circuit and Supreme Court. He has argued and won two cases in the US Supreme Court. The first, *Kimble v. Marvel Enterprises* (2015), addressed a patent owner's ability to collect royalties that accrue after the expiration of its patent term. The second, *Kingdomware Technologies, Inc. v. United States* (2016), addressed veterans' preferences in VA contracting. These recent cases follow a long string of successes Mr. Saunders has had in high-stakes appeals. Prior highlights include helping to secure a complete reversal of a $1.67 billion patent-infringement verdict, against a leading biotechnology company on its flagship therapeutic and defending a patent on a drug portfolio with $600 million in annual U.S. sales. Mr. Saunders has also argued and won cases in the Federal Circuit and Ninth Circuit.

Law360 recognized Mr. Saunders as an Appellate MVP of the Year in 2015 and an Appellate Rising Star in 2016 and 2017. He was also recommended by *The Legal 500 United States* in 2016 and 2017 for his appellate practice. Mr. Saunders clerked for Justice Ruth Bader Ginsburg of the US Supreme Court and Judge Pierre N. Leval of the US Court of Appeals for the Second Circuit.

SESSION 2:
PATENT ELIGIBILITY IN A POST MAYO WORLD

DAVID TELLEKSON

Partner, Fenwick & West LLP

David Tellekson litigates technology disputes, including patent infringement and licensing disputes, for clients in the areas of biotechnology, pharmaceuticals, polymer chemistry and medical devices. In addition to his trial work, he also consults on patent strategy, opinions and due diligence.

David is a frequent writer and lecturer in areas of patent law and patent litigation. He has been selected as a Washington "Super Lawyer" in the area of Intellectual Property Litigation each year since 2008. From 2012-2017, Intellectual Asset Management magazine named David to the *IAM Patent 1000: The World's Leading Patent Practitioners*. He is also included in the list of IP Stars by Managing Intellectual Property from 2014-2017. Managing IP also honored David as Washington's Outstanding Litigator of the year at the 2018 Managing IP Americas Awards.

David is admitted to practice in Washington, New York, and Illinois (inactive), before the United States Supreme Court, the United States District Court of Appeals for the Federal Circuit and multiple district courts. He is also registered to practice before the United States Patent and Trademark Office. David is a Master Member of the Seattle Intellectual Property American Inn of Court.

EWA DAVISON, PH.D.

Associate, Fenwick & West LLP

Ewa Davison, Ph.D. focuses her practice on litigating patent matters for companies in the life sciences, biotechnology, pharmaceutical, and chemistry arenas. Ewa's experience includes resolving disputes in the federal district courts and at the PTAB. She has also successfully argued four appeals at the Federal and Ninth Circuits. Ewa has been honored as a Washington "Rising Star" in the area of Intellectual Property Litigation for the past three years.

Ewa received her J.D. with high honors from the University of Washington School of Law in 2007, where she served as a managing editor of the Washington Law Review. She earned a Ph.D. in biology in 2003 from the Massachusetts Institute of Technology, where she worked in the laboratory of Dr. H. Robert Horvitz, winner of the 2002 Nobel Prize in Physiology or Medicine. Ewa was awarded several academic distinctions while an undergraduate at Princeton University. She graduated summa cum laude with an A.B. degree in molecular biology in 1993.

Prior to joining Fenwick & West, Ewa clerked for the Honorable Richard C. Tallman of the Ninth Circuit Court of Appeals. She was previously an associate with Darby & Darby P.C. in Seattle.

Ewa is a member of the State Bar of Washington and she is registered in the U.S. Patent and Trademark Office as a patent attorney.

MATTHEW GORDON

Senior Director, Legal Affairs, Myriad Genetics

Mat Gordon is a Senior Director of Legal Affairs at Myriad Genetics, Inc. He has been at Myriad for the past six and a half years. In addition to overseeing general commercial legal matters, Mat also directs global prosecution of IP related to many Myriad products, including Genesight, Prolaris and myPath melanoma. Mat has experience in patent litigation support, including direct involvement in the *AMP v. Myriad* case that went to the Supreme Court in 2013. Before entering the legal profession, Mat earned his PhD in oncological sciences at the Huntsman Cancer Institute, and his JD *cum laude* from the University of Michigan law school. Prior to joining the legal team at Myriad, Mat was an associate in the Salt Lake City office of Stoel Rives, LLP.

ELIAS LAMBIRIS

Director, Global IP Litigation, Novozymes

Elias Lambiris is Director of Global IP Litigation at Novozymes, a world leader in biological solutions. Mr. Lambiris has over 25 years of experience in all phases of U.S. and foreign patent practice, including management of a multi-national patent department, development of global patent strategies, patent procurement, licensing, contract drafting and negotiation, client counseling, opinion work, litigation management, and all department operations and procedures. He has a B.S. in chemical engineering from the Columbia School of Engineering and Applied Science and a J.D. from the Georgetown University Law Center.

SESSION 3: FROM ALLEGATION TO ADJUDICATION: PREPARING FOR PATENT LITIGATION

STEVEN LIEBERMAN

Partner Specializing in Patent Litigation, Rothwell, Figg, Ernst & Manbeck, P.C.

Mr. Steven Lieberman is a partner specializing in patent litigation at the Washington, D.C. intellectual property firm of Rothwell Figg. He has served as lead counsel in hundreds of lawsuits in the district courts, the Federal Circuit, and before the International Trade Commission, including more than 30 Hatch-Waxman litigations. Mr. Lieberman also has considerable experience in post-grant proceedings. His clients span the pharmaceutical, biotech, media, and medical product fields.

On the generic side, he represented Mylan Pharmaceuticals, Inc. in patent litigations relating to, inter alia, buspirone, nifedipine, nitroglycerin patches, paclitaxel, ranitidine, diltiazem, cimetidine, and amlodipine. Mr. Lieberman's representation of Mylan in its patent and antitrust actions against Bristol-Myers Squibb arising from Bristol's improper listing of a buspirone metabolite patent in the Orange Book resulted in Bristol paying $535 million to settle antitrust claims brought against it by Mylan, 29 state Attorneys General, and private class action plaintiffs.

Mr. Lieberman also represents brand name companies in patent litigations. He represented Burroughs Wellcome Co. in a number of lawsuits, including actions relating to AZT (Retrovir) as a therapy for humans infected with the virus that causes AIDS, and AstraZeneca Inc. in an action brought by Schering relating to AstraZeneca's prostate cancer therapy, Casodex.

Mr. Lieberman currently serves as a member of the Sedona Conference Working Group 10 on biopharma litigation issues. He received a B.A. degree from Princeton University, *summa cum laude*, in 1980 and a J.D. degree from Columbia University Law School in 1984 (Stone Scholar all three years).

JENNIFER P. NOCK

Associate, Rothwell, Figg, Ernst & Manbeck, P.C.

Jennifer P. Nock is an associate at the intellectual property law firm of Rothwell Figg in Washington, D.C. Ms. Nock is experienced in a variety of patent matters including litigation, prosecution, licensing, opinions, and counseling. While she has experience working with patents in a wide range of technical fields, her practice is particularly focused on pharmaceuticals. Ms. Nock has worked on numerous Hatch-Waxman litigations, both in district court and on appeal to the Federal Circuit, as well as patent interferences and IPRs involving pharmaceuticals and biological products. Her practice also includes due diligence studies of pharmaceutical and biological patent portfolios for potential acquisitions.

From 2012-2013, Ms. Nock served as a law clerk to Chief Judge Randall R. Rader at the United States Court of Appeals for the Federal Circuit.

Ms. Nock graduated from the George Washington University Law School in 2010, with highest honors. Prior to attending law school, Ms. Nock worked in university technology licensing for six years. That experience provided her an opportunity to work at the intersection of law, business, and science by promoting and transferring nascent university inventions to investors and existing companies.

Ms. Nock holds undergraduate degrees in physics and chemistry from the University of Richmond. Ms. Nock also holds a Master's degree in Chemistry from Harvard University, where she worked in the laboratory of George M. Whitesides on research involving surface chemistry, mesoscale self-assembly, and microfluidics.

DAN TROY

Senior Vice President & General Counsel, GlaxoSmithKline

Since 2008, Dan has been Senior Vice President & General Counsel and a member of the Corporate Executive Team of GSK. He will be leaving GSK as of the end of the year. As General Counsel, he is responsible for leading the company's legal department in protecting GSK's intellectual property, managing litigation, supporting business development transactions, as well as risk management.

Before joining GSK, he was a Partner at the Washington law firm Sidley Austin LLP, where he represented pharmaceutical companies and trade associations on matters related to the US Food and Drug Administration (FDA) and government regulations. Dan was formerly Chief Counsel for the FDA.

Dan holds a bachelor's degree in Industrial and Labor Relations from Cornell University and a juris doctor degree from Columbia University School of Law, where he was a member of the Law Review and a Kent Scholar. After graduation from law school, he was a law clerk for the US Circuit Court of Appeals for the District of Columbia Circuit. He was the 2012 CPR Corporate Leadership Award recipient and, in 2013, was named a 'Legend in the Law' at the Burton Awards.

JOHN WEIDENBRUCH

General Counsel, Epizyme

John Weidenbruch is General Counsel at Epizyme, a publicly traded clinical-stage biopharmaceutical company in Cambridge, Massachusetts, where he leads a team of contract and IP attorneys. Epizyme is committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines.

Mr. Weidenbruch has more than two decades of legal experience working in-house in the biotechnology industry. Prior to joining Epizyme in August 2017, he served as General Counsel at Visterra, a privately-held venture capital backed clinical-stage company developing infectious disease therapeutics. Mr. Weidenbruch was Vice President, Chief Global Commercial Counsel at Biogen from September 2010 through July 2015. Prior to joining Biogen, he was Executive Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer at Idenix Pharmaceuticals, a public biopharmaceutical company. Previously, Mr. Weidenbruch was General Counsel at Abraxis BioScience, and he spent more than ten years at Amgen, where he held positions of increasing responsibility in the legal and healthcare policy departments. Previously, he supported the state government affairs team at Syntex Laboratories, and began his career in the bio/pharmaceutical world as a lobbyist in Washington, DC with the Non-Prescription Drug Manufacturers Association.

Mr. Weidenbruch received a J.D. from Georgetown University Law Center and a B.A. from Loyola University Maryland.

SESSION 4:
WHAT'S ON THE HORIZON?
A FIRESIDE CHAT WITH CHIEF JUDGE RUSCHKE

BARBARA FIACCO

Parter, Foley Hoag LLP

Barbara Fiacco represents clients in complex intellectual property and patent litigation matters. Her technology-related practice focuses on the biomedical field, including counsel to companies with activities focusing on recombinant DNA, monoclonal antibodies, small molecule compounds, drug delivery, molecular diagnostics, and medical devices. She has defended pharmaceutical and life sciences clients in significant patent infringement lawsuits that have resulted in summary judgment or other favorable outcomes for her clients. Barbara also represents these clients in contract disputes and other commercial litigation.

THE HONORABLE DAVID RUSCHKE

Chief Judge for the Patent Trial and Appeal Board,
US Patent and Trademark Office

David P. Ruschke is Chief Judge for the Patent and Trial Appeal Board (PTAB). He was appointed to the position in May 2016.

As Chief Judge, Dr. Ruschke leads the PTAB which is authorized to conduct post-grant trials following the passage of the American Invents Act in 2011. Dr. Ruschke manages the PTAB as it conducts trials, including inter partes, post-grant, and covered business method patent reviews and derivation proceedings, hears appeals from adverse examiner decisions in patent applications and reexamination proceedings, and renders decisions in interferences.

In his previous role, Dr. Ruschke managed the intellectual property portfolio of Medtronic's CSH business unit, with sales in excess of $3 billion. As Chief Patent Counsel, Dr. Ruschke participated in numerous patent appeals, interferences, post grant reviews, inter partes reviews, and covered business method patent reviews. He gained extensive experience in post-grant proceedings in Europe and participated in third-party contested proceedings before administrative agencies and courts around the world. He has significant experience in shaping and integrating teams of professionals, as well as managing a workforce that is geographically dispersed.

Prior to joining Medtronic, Dr. Ruschke practiced with Covington & Burling in Washington DC, where he litigated claims of patent infringement. Dr. Ruschke's judicial experience includes clerking for Chief Judge Glenn L. Archer, Jr. and Circuit Judge Arthur J. Gajarsa at the U.S. Court of Appeals for the Federal Circuit.

Dr. Ruschke received his JD from Georgetown University Law Center, and holds a PhD in organometallic chemistry from the Massachusetts Institute of Technology and a BS in chemistry from the University of Minnesota.

SESSION 5:
DID YOU FORGET ANYTHING? DEALING WITH THE OVERLOOKED PROVISIONS OF THE AIA

DONALD R. WARE

Partner and Chair of the Patent Litigation Group,
Foley Hoag, LLP

Don Ware heads the firm's Patent Litigation practice, and is a past member of the firm's Executive Committee. Don represents leading biopharma manufacturers, research institutions, and universities in patent and inventorship disputes, technology transfer issues, and intellectual property strategy. He also advises clients on FDA matters, including the FDA's regulatory pathway for approval of biosimilars, and issues arising under the Bayh-Dole Act. He has represented the patent holders in several Bayh-Dole March-In proceedings, including the first such proceeding, *In re CellPro, Inc.*

REBECCA M. MCNEILL

Founding Partner, McNeill Baur PLLC

Rebecca M. McNeill is a Founding Partner of McNeil Baur PLLC. With more than 22 years of experience in biotechnology patent prosecution and counseling, Rebecca offers IP strategy, new application preparation, patent prosecution (US and foreign), preparation and negotiation of IP transactions, USPTO contentious practice, and the full scope of counseling services to clients of various sizes. She has worked with biotech start-ups, research foundations, universities, and pharmaceutical companies, ranging from early-stage to publicly-traded companies. She earned a B.A. in biology from Oberlin College, a M.S. in pharmacology from Duke University, and her law degree from Georgetown University Law Center.

JANE E. REMILLARD

Partner, Nelson Mullins Riley & Scarborough LLP

Jane E. Remillard is a Partner with Nelson Mullins Riley & Scarborough LLP. She has over 25 years of experience providing worldwide patent counseling and strategic planning, including patent prosecution, freedom to operate evaluations, opinion work, financial offerings, agreements, licensing, due diligence, interferences, re-examinations, reissues, inter-partes reviews, and oppositions involving a variety of biotechnologies, particularly antibody-based therapeutics. She earned a B.A. in molecular biology from Princeton University and her law degree from Boston University School of Law.

SESSION 6:
IF A TREE FALLS IN THE FOREST, DOES IT MAKE A SOUND? MYTHS AND REALITIES OF "EVERGREENING" PATENTS

MELANIE MAYER

Partner, Fenwick & West LLP

Melanie Mayer's practice focuses on intellectual property litigation and dispute resolution. She also analyzes patent issues for various due diligence matters and advises on freedom to operate issues. Melanie has litigated cases in a wide range of technologies, from biotechnology to ecommerce and high performance computing systems. Melanie has particular experience in life sciences matters, including those related to pharmaceuticals, enzyme variants, polymers, and drug screening and delivery platforms.

Melanie recently represented Cray, Inc. in a landmark venue decision from the Federal Circuit setting forth the standard for determining what constitutes a "regular and established place of business" under 28 U.S.C. § 1400(b).

Before attending law school, Melanie worked in biotechnology and earned a Ph.D. in molecular biology and genetics from the Johns Hopkins School of Medicine. She also has a B.S. in biochemistry. Melanie's strong technical background allows her to understand her client's technology at a sophisticated level and then to effectively communicate those complex technical issues to a judge or jury.

Melanie has also been recognized for her pro bono work. In 2015, Melanie was awarded the Outstanding Volunteer in Public Service Award by the Justice & Diversity Center of the Bar Association of San Francisco. In 2014, she obtained a significant settlement for a California state prisoner who was denied medical care for appendicitis and a ruptured appendix. Melanie also assists the ACLU and the Northwest Innocence Project.

PAUL FEHLNER

Principal, Life Sciences Innovation LLC

Paul Fehlner is a lawyer and Principal of Life Sciences Innovation LLC, a consulting company he founded in 2017 to advise on complex IP business strategy for products and technologies in life sciences, develop capabilities of legal and IP professionals, and provide BD&L support for research institutes, companies, and investors.

Previously, Dr. Fehlner was Head of Intellectual Property for Novartis Pharma in Basel, Switzerland. In this role, he led a team responsible for obtaining, maintaining, and enforcing IP rights. The team created holistic portfolios of patents, trademarks, regulatory exclusivities, and reputation for Novartis products. He has been named to the IAM Strategy 300 World's Leading Patent Professionals for the past three years.

Dr. Fehlner joined Novartis in 2008 from Baker Botts, where he was a partner specializing in IP counselling and strategic planning in the pharmaceutical, biotechnology and medical device industries, as well as litigation. Prior to that he was an associate and partner at Darby & Darby, with earlier experience as Biotechnology Counsel for Rhône-Poulenc Rorer and as an associate for IP firm Klauber & Jackson. Dr. Fehlner started his career in 1990 as a law clerk in the biotech and pharmaceutical group at Pennie & Edmonds. In addition to life sciences, Dr. Fehlner has worked on chemical and material sciences technologies.

Dr. Fehlner has a JD from Fordham University School of Law, a PhD in immunology and biochemistry from Rockefeller University (Lois P Markey Fellow), and a BS in chemistry from Haverford College (high honors; *Phi Beta Kappa*).

HANS SAUER, PH.D., J.D.

Deputy General Counsel and Vice President for Intellectual Property, Biotechnology Innovation Organization

Hans Sauer is Deputy General Counsel and Vice President for Intellectual Property for the Biotechnology Innovation Organization. At BIO, Mr. Sauer advises the organization's board of directors, amicus committee, and various staff committees on patent and other intellectual property-related matters. Prior to taking his current position at BIO in 2006, Professor Sauer was Chief Patent Counsel for MGI Pharma, Inc., and Senior Patent Counsel for Guilford Pharmaceuticals Inc. Mr. Sauer has 20 years of professional in-house experience in the biotechnology industry, where he worked on several drug development programs, being responsible for patent prosecution and portfolio oversight, clinical trial health information privacy, and sales and marketing legal compliance. Hans did his postdoctoral fellowship at Genentech, Inc. in South San Francisco, and holds a M.S. degree from the University of Ulm in his native Germany; a Ph.D. in Neuroscience from the University of Lund, Sweden; and a J.D. degree from Georgetown University Law Center.

Speaker Biographies | Session 6

CHUCK SHOLTZ

Vice President, Intellectual Property, Coherus Biosciences

Chuck Sholtz is Vice President, Intellectual Property at Coherus Biosciences, a biosimilar platform company. His responsibilities include managing the company's BPCIA and trade secret litigation, and providing intellectual property support for several Coherus pipeline products, including patent landscape assessments, design-around strategies, invalidity analyses and other aspects of intellectual property strategy. Prior to joining Coherus, Chuck served for eight years as Senior Counsel in the IP Law Group at Amgen, where he supported programs in both the innovator and biosimilar sides of the company. Before earning his law degree at Santa Clara University, he worked as a post-doctoral fellow in the Neurology Department at Massachusetts General Hospital and the Department of Genetics at Harvard Medical School. Chuck has Bachelor of Science degrees in Cellular and Molecular Biology, and in Engineering Science (Bioengineering) from the University of Michigan, a Masters in Physiology from Yale, and a PhD in Neuroscience from Stanford.

FORRESTERS
Clear direction

European and UK IP Specialists

We clarify European IP issues, and provide straightforward, business-directed advice.

We have extensive experience in biotechnology and chemistry IP. We provide advice on European and UK patent law including patentable subject matter, prosecution, opposition and appeals, supplementary protection certificates, due diligence and litigation.

Get in touch

T: +44 (0) 121 236 0484
E: birmingham@forresters.co.uk

T: +44 (0) 151 255 2180
E: liverpool@forresters.co.uk

T: +44 (0) 20 7283 8989
E: london@forresters.co.uk

T: +49 (0) 89 2441 2990
E: munich@forresters.co.uk

T: +44 (0) 238 030 2610
E: southampton@forresters.co.uk

forresters.co.uk

Follow us...